SCYNEXIS announced it will present eight new poster presentations on the company’s lead candidate SCY-078 at the ASM Microbe 2017.
SCYNEXIS (NASDAQ:SCYX) announced it will present eight new poster presentations on the company’s lead candidate SCY-078 at the ASM Microbe 2017.
As quoted in the press release:
SCY-078, the first representative of a novel intravenous (IV) and oral triterpenoid antifungal family in Phase 2 clinical development for the treatment of several fungal infections, including invasive candidiasis, invasive apergillosis and vulvovaginal candidiasis infections.
“Following an active ECCMID 2017, the large set of data to be presented further confirms the versatility of SCY-078 across treatment settings and against a wide array of Candida and Aspergillus fungal species,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “SCY-078’s compatibility in combination with other frequently used drugs and high tissue penetration into organ systems where infections occur are significant differentiators for this novel anti-infective. These presentations further support the potential broad applicability of SCY-078 and its ability to be a next-generation agent to fight these infections, including multi-drug-resistant pathogens such as Candida auris.”